JCAR015

DRUG2 trials

Sponsors

Juno Therapeutics, a Subsidiary of Celgene, Celgene

Conditions

Acute Lymphoblastic LeukemiaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 1

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

WithdrawnNCT02973191

CelgenePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Start: 2016-12-20End: 2021-01-24Updated: 2017-04-10

Unknown Phase

Long-Term Follow-up Study for Patients Previously Treated With JCAR015

CompletedNCT02813252

Juno Therapeutics, a Subsidiary of CelgeneAcute Lymphoblastic Leukemia

Start: 2016-08-30End: 2021-10-22Updated: 2022-06-03